Ross Aarons is a Director in the Corporate Development team at Jazz, where he leads Jazz’s oncology BD efforts. Ross joined Jazz in 2022, and has since led the execution of multiple strategic transactions to grow Jazz’s oncology pipeline, including a licensing agreement with Zymeworks for zanidatamab, an investigational HER2 bispecific antibody, as well as the acquisition of Redx’s KRAS inhibitor program. Prior to Jazz, Ross was a member of the Business Development & Acquisitions team at AbbVie, where he helped lead strategic transactions across a number of therapeutic areas. Ross received his B.S. in finance and economics from Penn State University and an MBA from the Kellogg School of Business at Northwestern University.